These users report appreciating treatment benefits while active but watching improvements gradually fade over months post-discontinuation, with timeline showing first 2 months maintaining most benefits creating initial optimism, months 2-4 showing noticeable decline returning toward baseline, months 4-8 continuing regression approaching pre-treatment status, and stabilization occurring 60-80% back toward original baseline with only modest long-term improvement retention
Serious side effects include muscle weakness, extreme thirst, confusion, shortness of breath, headache, exhaustion, reddening of the skin, and a fast or irregular heartbeat
As early as 1998, cytochrome P450 was introduced within HSV-I, enabling conversion processes whereby cyclophosphamide becomes activated specifically inside malignant tissues, leading toward notable anticancer effects evidenced across medulloblastoma atypical teratoid/rhabdomyosarcoma brain neoplasms among others (105, 106)
Kiste A
